NeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator

MT Newswires Live

Oct 07, 2025

NeuroScientific Biopharmaceuticals (ASX:NSB) said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell (MSC) technology, according to a Tuesday Australian bourse filing.

Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573392439"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573392439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573392439?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 12:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573392439","market":"sg","top_or_hot":-1,"title":"NeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator","media":"MT Newswires Live","content":"<html><body><p> NeuroScientific Biopharmaceuticals (ASX:NSB) said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell (MSC) technology, according to a Tuesday Australian bourse filing.</p><p>Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-07 12:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> NeuroScientific Biopharmaceuticals (ASX:NSB) said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell (MSC) technology, according to a Tuesday Australian bourse filing.</p><p>Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4150","symbol_name":"赌场与赌博","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2573392439","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573392439","pubTimestamp":1759812275,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"NeuroScientific Biopharmaceuticals  said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell  technology, according to a Tuesday Australian bourse filing.Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4150":"赌场与赌博","NSB.AU":"NEUROSCIENTIFIC BIOPHARMACEU","XJO.AU":"标普/澳交所 200指数","XAO.AU":"标普/澳交所 普通股指数","BK7067":"生物科技","XKO.AU":"标普/澳交所 300指数","MSC":"新濠影汇","BK4575":"芯片概念"},"translate_title":"NeuroScientific表示，用于克罗恩病患者造瘘的StemSmart疗法已获得澳大利亚监管机构批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NSB.AU":1,"MSC":1,"XJO.AU":1.5,"XAO.AU":1.5,"XKO.AU":1.5},"content_text":"NeuroScientific Biopharmaceuticals (ASX:NSB) said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell (MSC) technology, according to a Tuesday Australian bourse filing.Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}